Chou H C, Lang N P, Kadlubar F F
Office of Research (HFT-100), National Center for Toxicological Research, Jefferson, AR 72079.
Carcinogenesis. 1995 Feb;16(2):413-7. doi: 10.1093/carcin/16.2.413.
The role of human sulfotransferase(s) in the bioactivation of the N-hydroxy (N-OH) metabolite of the human bladder carcinogen 4-aminobiphenyl (ABP) was investigated in vitro with human tissue cytosols. Using an enzymatic assay consisting of a PAPS-regenerating system, [3H]N-OH-ABP, calf thymus DNA and tissue cytosols, the sulfotransferase-mediated metabolic activation of N-OH-ABP was determined as the PAPS-dependent covalent binding of the N-OH substrate to DNA. With cytosols prepared from various tissues, we found that the sulfotransferase(s) in human liver, and to a lesser extent colon, can readily metabolize N-OH-ABP. No PAPS-dependent metabolic activation was detected with cytosols prepared from human pancreas or from the carcinogen target tissue, the urinary bladder epithelium. The N-OH-ABP sulfotransferase activities of liver and colon cytosols from different individuals were highly correlated with their thermostable phenol sulfotransferase (TS-PST) activity (liver, r = 0.99, P < 0.01; colon, r = 0.88, P < 0.01), but not with activities for the thermolabile phenol sulfotransferase (TL-PST; liver, r = 0.29; colon, r = 0.53), or for the dehydroepiandrosterone sulfotransferase (DHEA-ST; liver, r = 0.32; colon, negligible activity). N-OH-ABP sulfotransferase activity was highly sensitive to inhibition by a selective TS-PST inhibitor, 2,6-dichloro-4-nitrophenol (IC50 = 0.7 microM), and by p-nitrophenol, but was unaffected by competitive inhibitors of TL-PST (dopamine) or DHEA-ST (DHEA, DHEA-sulfate). The N-OH-ABP sulfotransferase activity also exhibited thermostability properties similar to that of the TS-PST. From these data, we conclude that human liver TS-PST but not TL-PST or DHEA-ST can metabolically activate the proximate human carcinogen N-OH-ABP to a reactive sulfuric acid ester intermediate that binds covalently to DNA. In addition, in view of the putative role of N-OH-ABP as a major transport form of the carcinogen to the urinary bladder and of the absence of sulfotransferase activity in this tissue, we hypothesize that sulfotransferase activation in the liver may actually decrease the bioavailability of N-OH-ABP toward extrahepatic tissues and thus serve as an important overall detoxification mechanism for the urinary bladder.
利用人体组织胞质溶胶在体外研究了人磺基转移酶在人膀胱癌致癌物4-氨基联苯(ABP)的N-羟基(N-OH)代谢物生物活化中的作用。采用由PAPS再生系统、[3H]N-OH-ABP、小牛胸腺DNA和组织胞质溶胶组成的酶促测定法,将磺基转移酶介导的N-OH-ABP代谢活化确定为N-OH底物与DNA的PAPS依赖性共价结合。用从各种组织制备的胞质溶胶,我们发现人肝脏中的磺基转移酶以及程度稍低的结肠中的磺基转移酶能够轻易代谢N-OH-ABP。用人胰腺或致癌物靶组织膀胱上皮制备的胞质溶胶未检测到PAPS依赖性代谢活化。来自不同个体的肝脏和结肠胞质溶胶的N-OH-ABP磺基转移酶活性与其热稳定酚磺基转移酶(TS-PST)活性高度相关(肝脏,r = 0.99,P < 0.01;结肠,r = 0.88,P < 0.01),但与热不稳定酚磺基转移酶(TL-PST;肝脏,r = 0.29;结肠,r = 0.53)或脱氢表雄酮磺基转移酶(DHEA-ST;肝脏,r = 0.32;结肠,活性可忽略不计)的活性无关。N-OH-ABP磺基转移酶活性对选择性TS-PST抑制剂2,6-二氯-4-硝基苯酚(IC50 = 0.7 microM)和对硝基苯酚的抑制高度敏感,但不受TL-PST(多巴胺)或DHEA-ST(DHEA、DHEA-硫酸盐)竞争性抑制剂的影响。N-OH-ABP磺基转移酶活性也表现出与TS-PST相似的热稳定性特性。根据这些数据,我们得出结论,人肝脏TS-PST而非TL-PST或DHEA-ST能够将人近端致癌物N-OH-ABP代谢活化为与DNA共价结合的活性硫酸酯中间体。此外,鉴于N-OH-ABP作为致癌物向膀胱的主要转运形式的假定作用以及该组织中缺乏磺基转移酶活性,我们推测肝脏中的磺基转移酶活化实际上可能会降低N-OH-ABP对肝外组织的生物利用度,从而作为膀胱重要的整体解毒机制。